(RTTNews) - RedHill Biopharma Ltd. (RDHL) reported preliminary results of a preclinical study showing strong inhibition by opaganib of COVID-19 Delta variant replication while maintaining cell viability at relevant concentrations. Opaganib is a small molecule investigational oral pill in development for the treatment of COVID-19. The company said this data from a human bronchial epithelial cells model adds to prior data showing potent inhibition of all COVID-19 variants tested to date.
RedHill Biopharma said Opaganib's global phase 2/3 study in hospitalized patients with COVID-19 has completed its treatment and follow up phase, and study top-line results are upcoming.
Shares of RedHill Biopharma were up 15% in pre-market trade on Thursday.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
